FDA Approves Leqembi Iqlik Subcutaneous Initiation

Eisai and Biogen have secured FDA approval for a weekly subcutaneous initiation dose of Leqembi (lecanemab-irmb), branded Leqembi Iqlik, for the treatment of early Alzheimer’s disease. Announced on 14 July 2026, the supplemental biologics licence application clears an autoinjector-delivered alternative to intravenous dosing from the start of treatment, and gives the anti-amyloid therapy the only at-home administration option available across the Alzheimer’s disease treatment pathway.

The approved regimen delivers 500 mg once weekly as two 250 mg injections, each administered in around 15 seconds. Leqembi Iqlik can also be used for maintenance dosing at 360 mg once weekly after 18 months of intravenous or subcutaneous treatment, with patients able to switch between IV and subcutaneous routes throughout the treatment course. The approval is supported by sub-studies of the Clarity AD phase 3 long-term extension, which showed once weekly subcutaneous dosing achieved exposure equivalent to IV administration, with comparable rates of ARIA-E and no increase in isolated ARIA-H versus placebo.

Howard Fillit, Co-Founder and Chief Science Officer Emeritus of the Alzheimer’s Drug Discovery Foundation, framed the approval as opening a new era of Alzheimer’s treatment where patients and care partners have genuine choice over how anti-amyloid therapy is delivered. Eisai and Biogen expect the subcutaneous option to reduce clinic visit burden, reliance on infusion resources, and clinical preparation and monitoring time, while preserving infusion capacity for patients who prefer or require IV therapy. An autoinjector acceptability study found 94% of patients and care partners rated the device easy to use.

The commercial signal is Eisai and Biogen removing one of the biggest practical barriers to anti-amyloid therapy adoption. Infusion capacity and clinic-visit burden have been repeatedly cited by neurologists as constraints on Leqembi uptake since its 2023 approval, and at-home autoinjection materially widens the addressable patient pool. Expect similar subcutaneous strategies from Eli Lilly’s Kisunla programme as competitive pressure intensifies.

For the latest updates and in-depth insights into the world of Pharmaceutical, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!